EVOKE PHARMA, INC. Selling, General and Administrative Expense
EVOKE PHARMA, INC. reported Selling, General and Administrative Expense of $5.31 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2025-11-13
- EVOKE PHARMA, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $5.31M, a 38.97% increase year-over-year.
- EVOKE PHARMA, INC. selling, general and administrative expense for the quarter ending 2025-06-30 was $5.13M, a 37.54% increase year-over-year.
- EVOKE PHARMA, INC. selling, general and administrative expense for the quarter ending 2025-03-31 was $4.30M, a 36.88% increase year-over-year.
- EVOKE PHARMA, INC. selling, general and administrative expense for the quarter ending 2024-12-31 was $4.38M, a 25.88% increase year-over-year.
- EVOKE PHARMA, INC. selling, general and administrative expense for fiscal 2024 was $15.08M, a 23.33% increase from fiscal 2023.
- EVOKE PHARMA, INC. selling, general and administrative expense for fiscal 2023 was $12.23M, a 27.06% increase from fiscal 2022.
- EVOKE PHARMA, INC. selling, general and administrative expense for fiscal 2022 was $9.62M, a 8.73% increase from fiscal 2021.
- EVOKE PHARMA, INC. selling, general and administrative expense for fiscal 2021 was $8.85M, a 37.68% increase from fiscal 2020.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $5.31M 10-Q · filed 2025-11-13 | $10.45M derived: sum of 2 quarters · filed 2025-11-13 | $14.75M 10-Q · filed 2025-11-13 | $19.13M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | $5.13M 10-Q · filed 2025-08-14 | $9.43M 10-Q · filed 2025-08-14 | $13.82M derived: sum of 3 quarters · filed 2025-08-14 | $17.64M derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | $4.30M 10-Q · filed 2025-05-13 | $8.68M derived: sum of 2 quarters · filed 2025-05-13 | $12.51M derived: sum of 3 quarters · filed 2025-11-13 | $16.24M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $8.21M derived: sum of 2 quarters · filed 2025-11-13 | $11.94M derived: sum of 3 quarters · filed 2025-11-13 | $15.08M 10-K · filed 2025-03-13 |
| 2024-09-30 | $3.82M 10-Q · filed 2025-11-13 | $7.56M derived: sum of 2 quarters · filed 2025-11-13 | $10.70M 10-Q · filed 2025-11-13 | $14.18M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $3.73M 10-Q · filed 2025-08-14 | $6.87M 10-Q · filed 2025-08-14 | $10.36M derived: sum of 3 quarters · filed 2025-08-14 | $13.49M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $3.14M 10-Q · filed 2025-05-13 | $6.62M derived: sum of 2 quarters · filed 2025-05-13 | $9.75M derived: sum of 3 quarters · filed 2025-05-13 | $12.52M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $6.61M derived: sum of 2 quarters · filed 2025-03-13 | $9.38M derived: sum of 3 quarters · filed 2025-03-13 | $12.23M 10-K · filed 2025-03-13 |
| 2023-09-30 | $3.13M 10-Q · filed 2024-11-07 | $5.90M derived: sum of 2 quarters · filed 2024-11-07 | $8.75M 10-Q · filed 2024-11-07 | $11.03M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.77M 10-Q · filed 2024-08-13 | $5.61M 10-Q · filed 2024-08-13 | $7.90M derived: sum of 3 quarters · filed 2024-08-13 | $10.52M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.85M 10-Q · filed 2024-05-14 | $5.14M derived: sum of 2 quarters · filed 2024-05-14 | $7.75M derived: sum of 3 quarters · filed 2024-05-14 | $10.07M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $2.29M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-14 | $4.90M derived: sum of 2 quarters · filed 2024-05-14 | $7.22M derived: sum of 3 quarters · filed 2024-05-14 | $9.62M 10-K/A · filed 2024-05-14 |
| 2022-09-30 | $2.61M 10-Q · filed 2023-11-09 | $4.93M derived: sum of 2 quarters · filed 2023-11-09 | $7.33M 10-Q · filed 2023-11-09 | $9.07M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.32M 10-Q · filed 2023-08-10 | $4.72M 10-Q · filed 2023-08-10 | $6.46M derived: sum of 3 quarters · filed 2023-08-10 | $9.09M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $2.41M 10-Q · filed 2023-05-15 | $4.14M derived: sum of 2 quarters · filed 2023-05-15 | $6.78M derived: sum of 3 quarters · filed 2023-05-15 | $8.92M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $4.37M derived: sum of 2 quarters · filed 2023-03-21 | $6.51M derived: sum of 3 quarters · filed 2023-03-21 | $8.85M 10-K · filed 2023-03-21 |
| 2021-09-30 | $2.64M 10-Q · filed 2022-11-09 | $4.78M derived: sum of 2 quarters · filed 2022-11-09 | $7.12M 10-Q · filed 2022-11-09 | $9.16M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $2.14M 10-Q · filed 2022-08-10 | $4.48M 10-Q · filed 2022-08-10 | $6.52M derived: sum of 3 quarters · filed 2022-08-10 | $8.40M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $2.34M 10-Q · filed 2022-05-10 | $4.38M derived: sum of 2 quarters · filed 2022-05-10 | $6.25M derived: sum of 3 quarters · filed 2022-05-10 | $7.44M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $2.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $3.92M derived: sum of 2 quarters · filed 2022-03-08 | $5.10M derived: sum of 3 quarters · filed 2022-03-08 | $6.43M 10-K · filed 2022-03-08 |
| 2020-09-30 | $1.87M 10-Q · filed 2021-11-10 | $3.06M derived: sum of 2 quarters · filed 2021-11-10 | $4.39M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.18M 10-Q · filed 2021-08-12 | $2.51M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.33M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $3.74M 10-K · filed 2021-03-11 |